How does ARIX's PE Ratio compare to its peers?

ARIX is good value based on its Price-To-Earnings Ratio (11.8x) compared to the peer average (26.5x).

How does ARIX's PE Ratio compare vs other companies in the GB Capital Markets Industry?

ARIX is good value based on its Price-To-Earnings Ratio (11.8x) compared to the UK Capital Markets industry average (14x).

What is ARIX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ARIX's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of ARIX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ARIX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Arix Bioscience (LSE:ARIX) - Stock Price, News & Analysis

ARIX Stock Overview

ARIX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (11.8x) is below the UK market (15.2x)

Became profitable this year

Risk Analysis

Earnings have declined by 16.4% per year over past 5 years

Arix Bioscience plc Competitors

Rights and Issues Investment Trust

LSE:RIII

UK£114.9m

TMT Investments

AIM:TMT

US$93.4m

Schroder BSC Social Impact Trust

LSE:SBSI

UK£65.5m

City of London Investment Group

LSE:CLIG

UK£190.5m

Price History & Performance

Summary of all time highs, changes and price drops for Arix Bioscience
Historical stock prices
Current Share Price	UK£1.42
52 Week High	UK£1.45
52 Week Low	UK£0.97
Beta	1.05
11 Month Change	6.77%
3 Month Change	28.51%
1 Year Change	22.41%
33 Year Change	-31.73%
5 Year Change	-12.88%
Change since IPO	-32.06%

Recent updates

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Jan 13

Shareholder Returns

	ARIX	GB Capital Markets	GB Market
7D	-1.0%	2.6%	2.2%
1Y	22.4%	26.5%	8.0%

Return vs Industry: ARIX exceeded the UK Capital Markets industry which returned 3% over the past year.

Return vs Market: ARIX exceeded the UK Market which returned -5.7% over the past year.

Price Volatility

Is ARIX's price volatile compared to industry and market?
ARIX volatility
ARIX Average Weekly Movement	2.6%
Capital Markets Industry Average Movement	3.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: ARIX has not had significant price volatility in the past 3 months.

Volatility Over Time: ARIX's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	9	n/a	arixbioscience.com

Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally.

Arix Bioscience plc Fundamentals Summary

How do Arix Bioscience's earnings and revenue compare to its market cap?
ARIX fundamental statistics
Market cap	UK£176.52m
Earnings (TTM)	UK£14.96m
Revenue (TTM)	UK£14.16m

11.8x

P/E Ratio

12.5x

P/S Ratio

Is ARIX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARIX income statement (TTM)
Revenue	UK£14.16m
Cost of Revenue	UK£0
Gross Profit	UK£14.16m
Other Expenses	-UK£799.00k
Earnings	UK£14.96m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0.12
Gross Margin	100.00%
Net Profit Margin	105.64%
Debt/Equity Ratio	0%

How did ARIX perform over the long term?

See historical performance and comparison

ARIX Stock Overview

Rewards

Risk Analysis

Arix Bioscience plc Competitors

LSE:RIII

UK£114.9m

AIM:TMT

US$93.4m

LSE:SBSI

UK£65.5m

LSE:CLIG

UK£190.5m

Price History & Performance

Recent News & Updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought UK£69k worth of stock

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Recent updates

Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc. (NasdaqCM:HARP).

Arix Bioscience plc Announces Resignation of Directors

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Independent Non-Executive Chairman recently bought UK£69k worth of stock

First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)

Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023

Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023

New minor risk - Insider selling

Independent Non-Executive Chairman recently bought UK£77k worth of stock

Full year 2022 earnings released

Independent Non-Executive Chairman recently bought UK£217k worth of stock

Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive Director

Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders.

Price target increased to UK£2.56

Less than half of directors are independent

Independent Non-Executive Chairman recently bought UK£78k worth of stock

Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. (NasdaqGM:LOGC) from a group of shareholders for $68.2 million.

First half 2022 earnings released

Arix Bioscience plc Announces Board and Committee Changes

Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022

Arix Bioscience plc, Annual General Meeting, Jun 07, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022

Price target increased to UK£2.56

Less than half of directors are independent

Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The Market

Price target increased to UK£2.56

Managing Director Christian Schetter has left the company

First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)

Executive Chairman Naseem Amin has left the company

Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)

Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021

Investor sentiment improved over the past week

New 90-day high: UK£2.22

Executive Chairman recently bought UK£377k worth of stock

Investor sentiment improved over the past week

New 90-day high: UK£1.96

Market bids up stock over the past week

Analysts update estimates

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.

Market bids up stock over the past week

New 90-day high: UK£1.60

Price target raised to UK£1.71

New 90-day high: UK£1.12

New 90-day high - UK£0.97

Price target raised to UK£1.40

Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020

Shareholder Returns

Price Volatility

About the Company

Arix Bioscience plc Fundamentals Summary

11.8x

12.5x

Earnings & Revenue